|
|
Post by mango on Apr 22, 2020 14:43:11 GMT -5
New MannKind Granted Patent 4/21/20 Blister package for pharmaceutical cartridgesAbstract: A blister packaging for a pharmaceutical cartridge or capsule and methods of forming same are disclosed.
Type: Grant
Filed: December 3, 2014
Date of Patent: April 21, 2020
Assignee: MannKind Corporation
Inventor: Michael S. Bergey
patents.justia.com/patent/10625034 |
|
|
|
Post by mango on May 14, 2020 12:32:09 GMT -5
New MannKind Granted Patent 5/14/20 HIGH CAPACITY DIKETOPIPERAZINE MICROPARTICLES AND METHODSAbstract: Disclosed herein are diketopiperazine microparticles having high capacity for adsorbing a drug or active agent. In particular, the diketopiperazine microparticle are formed using fumaryl diketopiperazine and can comprise a drug in large doses for the treatment of disease or disorders by pulmonary delivery via oral inhalation. Type: Application Filed: January 10, 2020 Publication date: May 14, 2020 Applicant: MannKind Corporation Inventors: Marshall Grant, Paul Menkin, Grayson W. Stowell patents.justia.com/patent/20200147221 |
|
|
|
Post by mango on Aug 19, 2020 13:36:05 GMT -5
|
|
|
|
Post by itellthefuture777 on Aug 19, 2020 16:53:37 GMT -5
|
|
|
|
Post by longliner on Aug 19, 2020 17:22:56 GMT -5
One long acting puff in the morning, mealtime puffs for the remainder of the day. Just in time for pediatrics. |
|
|
|
Post by mango on Sept 16, 2020 20:57:30 GMT -5
|
|
|
|
Post by mango on Sept 16, 2020 21:01:07 GMT -5
From the second one listed above:
12. The dry powder inhaler of claim 9 wherein the one or more active agent is granulocyte macrophage colony stimulating factor.
|
|
|
|
Post by biffn on Sept 16, 2020 22:33:07 GMT -5
Covid From the second one listed above: 12. The dry powder inhaler of claim 9 wherein the one or more active agent is granulocyte macrophage colony stimulating factor. |
|
|
|
Post by mango on Oct 16, 2020 13:03:29 GMT -5
New International MannKind Cannabinoid patent published 1/10/20 INHALABLE DRY POWDERSWe claim: 1. A dry powder pharmaceutical composition comprising microcrystalline particles of 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine and a cannabinoid; wherein the cannabinoid is in an amount from 1% to 40% (w/w) of the total weight of the composition. 2. The dry powder pharmaceutical composition of claim 1, wherein the cannabinoid is one or more of tetrahydrocannabinol, cannabidiol, or cannabinol, or combinations thereof. 3. The dry powder pharmaceutical composition of claim 1, wherein the dry powder further comprises a phospholipid selected from l,2-dipalmitoyl-5«-glycero-3-phosphocholine and 1 ,2-distearoyl-.s//-glycero-3-phosphocholine. 4. The dry powder pharmaceutical composition of claim 1, wherein the microcrystalline particles have an average pore volume of about 0.36 cmVg to about 0.43 cmVg. 5. The dry powder pharmaceutical composition of claim 1, wherein the microcrystalline particles have an average pore size from about 23 nm to about 28 nm. 6. The dry powder pharmaceutical composition of claim 1, wherein microcrystalline particles have a surface area of ranges from about 59 m2/g to about 63 m2/g. 7. The dry powder pharmaceutical composition of claim 1, wherein the microcrystalline particles have average pore volumes of about 0.43 cm3/g and average pore size ranging from about 23.8 nm to 26.2 nm as determined by BJH adsorption. 8. A dry powder inhaler comprising a dry powder pharmaceutical composition comprising microcrystalline particles of 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine comprising tetrahydrocannabinol, cannabidiol, or cannabinol in an amount from 1% to about 40% (w/w) of the total content of the dry powder. 9. The dry powder inhaler of claim 8, wherein the dry powder further comprises a phospholipid selected from l,2-dipalmitoyl-5«-glycero-3-phosphocholine and 1,2-distearoyl-.s//-glycero-3-phosphocholine in an amount up to about 15% (w/w) in the composition. 10. A method of treating chronic pain comprising, administering to a patient in need of treatment a therapeutically effective amount of the dry powder pharmaceutical composition of claim 1 by oral inhalation using a dry powder inhaler. 11. A dry powder drug delivery system comprising a dry powder inhaler comprising a dry powder pharmaceutical composition comprising microcrystalline particles of 3,6-bis(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine and a cannabinoid; wherein the cannabinoid is in an amount from 1% to 40% (w/w) of the total weight of the composition and the microcrystalline particles have average pore volumes of about 0.43 cm3/g and average pore size ranging from about 23.8 nm to 26.2 nm as determined by BJH adsorption. patentscope.wipo.int/search/en/detail.jsf?docId=WO2020198051&_cid=P22-KGCK2G-78732-1 |
|
|
|
Post by Clement on Oct 16, 2020 14:02:05 GMT -5
Mango,
Is that Jan 10, 2020
Or is it Oct 1, 2020?
|
|
|
|
Post by uvula on Oct 16, 2020 14:12:46 GMT -5
The international filing date is
20.3.2020. So it must be day.month.year
|
|
|
|
Post by buyitonsale on Oct 16, 2020 16:43:56 GMT -5
If there is an RLS related announcement, any announcement what so ever, before TreT is approved (which will be Q4 2021 or Q1 2022), I will be very happy with that ... This partnership, so far, has been a well designed torture for investors that have been counting on it to come to fruition... since 2016... I am one of them.  |
|
|
|
Post by mango on Oct 16, 2020 19:50:38 GMT -5
Mango, Is that Jan 10, 2020 Or is it Oct 1, 2020? WIPO goes by [day] [month] [year] So it would be 1/10/20 |
|
|
|
Post by mango on Oct 16, 2020 19:53:14 GMT -5
If there is an RLS related announcement, any announcement what so ever, before TreT is approved (which will be Q4 2021 or Q1 2022), I will be very happy with that ... This partnership, so far, has been a well designed torture for investors that have been counting on it to come to fruition... since 2016... I am one of them. I agree. Pure torture. I hope we hear something grand from RLS soon! |
|
|
|
Post by uvula on Oct 16, 2020 20:02:02 GMT -5
I can't speak for anyone else but I have given up on making money from afrezza. Our best hope is for a separate company to license technosphere or a dreamboat for their drug.
Having said that, we are probably in a better position than we have been in a long time.
|
|
